STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Tailored radiation beams aim to shrink untreatable liver tumors
Disease control OngoingThis study tests a personalized approach to radiation therapy for liver cancer patients whose tumors cannot be removed by surgery. By customizing the radiation dose for each person, researchers hope to improve tumor shrinkage while protecting healthy liver tissue. The trial invol…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New drug combo shows promise in shrinking High-Risk liver tumors
Disease control OngoingThis phase 2 trial tests whether combining regorafenib (a drug that blocks cancer cell growth) with durvalumab (an immunotherapy that helps the immune system attack cancer) can shrink tumors in people with high-risk liver cancer. The study includes 4 adults with early-stage liver…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Immunotherapy duo after radiation shows promise for untreatable liver cancer
Disease control OngoingThis early-stage trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) after a targeted radiation treatment can help control advanced liver cancer that cannot be removed by surgery. The study involves 25 adults with liver cancer that has spread locally.…
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New combo shows promise for tough liver cancer
Disease control OngoingThis study tests a new drug called pevonedistat, given alone or with standard chemotherapy, in people with advanced bile duct cancer of the liver that has spread or cannot be removed. The goal is to see if the combination can shrink tumors. About 40 adults who have already tried …
Matched conditions: STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC